Management of Palatal Bleeding in Patients on Triple Antiplatelet Therapy

Initial Assessment and Management

• The American College of Cardiology recommends immediately stopping all antiplatelet agents and applying direct local hemostatic measures with gauze soaked in tranexamic acid and manual compression for a palatal bleed in a patient on triple antiplatelet therapy, and assessing for major bleeding criteria to determine if platelet transfusion or surgical intervention is needed 1, 2
• Determine immediately if the bleed is major by assessing for hemodynamic instability, hemoglobin decrease ≥2 g/dL, need for ≥2 units of RBC transfusion, or active bleeding that cannot be controlled with simple pressure 1, 2, 3
• The American College of Cardiology suggests that a palatal bleed is typically classified as non-major unless it meets the above criteria, but the oral cavity's vascularity and difficulty with compression warrant aggressive local management 1, 2, 3

Immediate Management Steps

• Discontinue all three antiplatelet agents immediately for any palatal bleeding, as the American College of Cardiology recommends stopping antiplatelet therapy even for non-major bleeds when local control is needed 1, 2, 3
• Clean the wound with sterile saline and apply gauze soaked with tranexamic acid directly to the bleeding site with gentle manual compression for 3-5 minutes 4
• Initiate volume resuscitation if hemodynamically unstable 1, 2
• Assess for and manage comorbidities that could contribute to bleeding (thrombocytopenia, uremia, liver disease) 1, 2, 3

Escalation Strategy if Local Measures Fail

• Consider ENT or oral surgery consultation for cauterization, suturing, or other procedural hemostasis if bleeding persists despite local measures and blood product support 1, 2, 4
• Target platelet count >50,000/μL if transfusing for active oral bleeding 4

Critical Pitfalls to Avoid

• Do not administer prothrombin complex concentrates (PCC), vitamin K, idarucizumab, or andexanet alfa, as these are for anticoagulant reversal, not antiplatelet therapy 1, 2

Restarting Antiplatelet Therapy

• Once hemostasis is achieved, carefully reassess the indication for triple antiplatelet therapy, as this regimen carries extremely high bleeding risk 1, 2

Monitoring Requirements

• Monitor closely for recurrent bleeding after initial hemostasis 4
• Check serial hemoglobin levels to detect ongoing occult bleeding 4
• Assess for signs of infection at the bleeding site 4
• Ensure proper healing before considering resumption of antiplatelet therapy 4